Menard Financial Group LLC Grows Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Menard Financial Group LLC boosted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,014 shares of the biotechnology company’s stock after buying an additional 24 shares during the period. Axon Enterprise makes up about 0.8% of Menard Financial Group LLC’s investment portfolio, making the stock its 29th largest holding. Menard Financial Group LLC’s holdings in Axon Enterprise were worth $1,204,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AXON. Westfield Capital Management Co. LP boosted its stake in Axon Enterprise by 12.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after buying an additional 83,265 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after acquiring an additional 9,090 shares in the last quarter. 1832 Asset Management L.P. raised its holdings in Axon Enterprise by 44.0% in the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after acquiring an additional 114,800 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in Axon Enterprise by 13.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after acquiring an additional 45,049 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 5.3 %

Axon Enterprise stock opened at $669.87 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm’s 50 day moving average price is $498.62 and its 200-day moving average price is $385.31. Axon Enterprise, Inc. has a 1 year low of $229.02 and a 1 year high of $675.47. The stock has a market cap of $51.08 billion, a P/E ratio of 173.09, a PEG ratio of 14.00 and a beta of 1.01.

Analyst Ratings Changes

AXON has been the subject of several recent analyst reports. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $500.00 to $700.00 in a research note on Tuesday. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Barclays raised their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. JMP Securities increased their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st. Finally, Craig Hallum upped their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus target price of $460.33.

Insiders Place Their Bets

In other news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now directly owns 98,825 shares in the company, valued at approximately $37,449,733.75. This represents a 4.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $353.53, for a total transaction of $318,177.00. Following the completion of the transaction, the director now directly owns 3,653 shares of the company’s stock, valued at approximately $1,291,445.09. This trade represents a 19.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 135,256 shares of company stock worth $61,043,370 in the last 90 days. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.